Kerry Group plc is a provider of taste and nutrition solutions across food and beverage markets. The company develops ingredients, flavors, and functional solutions for food, beverage, biotechnology, pharma, and proactive health sectors. Its portfolio includes value-add dairy ingredients and consumer products, with specific offerings in food protection, preservation, and pharma and life science solutions. Kerry serves customers globally, partnering with them to create products with improved nutrition, functionality, and reduced sugar or salt content. The company operates through its Kerry Health & Nutrition Institute and utilizes technologies such as Tastesense Advanced for sugar reduction. Kerry originated as a dairy company in Ireland before expanding into a global organization.

Summarised from the company's own disclosures, fiscal year ended Dec 2024

Industry Packaged Foods Homepage kerry.com
Sector Consumer Defensive IR page kerry.com/investors
Tags
flavoring, food ingredients, dairy ingredients, pharma solutions, life science, food preservation, nutrition solutions, clean label, sugar reduction, biotechnology, Kerry Health & Nutrition Institute, Tastesense Advanced
Press page kerry.com/about/news-and-media

Metrics

Valuation  
Market cap € 11.995B
Market cap (USD) $ 13.257B
P/E 19.19
PEG 6.85
P/BV 1.96
P/S 1.81
P/OCF 12.13
P/FCF —
Dividend yield 1.1%
Turnover / mcap —
Returns  
ROE 10.6%
ROI 11.1%
ROIC 11.1%
Profit margin 9.7%
Growth  
Revenue growing No
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) 2.8%
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 3
Quality score 11.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011
Revenue 6.758B 6.929B 8.02B 8.772B 7.351B 6.953B 7.241B 6.608B 6.408B 6.131B 6.105B 5.757B 5.837B 5.848B 5.302B
Net profit 658.8M 734.4M 728.1M 606.5M 763M 554.1M 566.5M 540.5M 588.5M 533.1M — — — — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011
Share price 89.11 109.1 89.59 106.41 129.69 — — — — — — — — — —
Price performance 12m -0.16 0.2 -0.15 -0.18 — — — — — — — — — — —

Filed figures

Figure Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024
Balance sheet detail
Trade receivables (EUR) — 1.04B 1.18B 1.42B 1.28B 1.24B
↳ YoY growth +13.4% +20.5% -10.2% -3.4%
Borrowings, current (EUR) — 2.8M 5.6M 701M 37.1M 950M
Borrowings, non-current (EUR) — 2.51B 3.12B 2.43B 2.43B 2.48B
Lease liabilities (EUR) — 81.5M 74.2M 69.2M 68.6M 86.6M
Cash and deposits (EUR) 550M 560M 1.03B 970M 909M 1.61B
Net debt (borrowings + leases - cash) (EUR) — 2.03B 2.16B 2.23B 1.63B 1.91B
Cash flow detail
Operating cash flow (EUR) — 672M 654M 722M 1.04B 989M
Dividends paid (cash effect) (EUR) — -143M -158M -174M -191M -205M
Share buybacks (cash effect) (EUR) — — — 0.00 -102M -557M
Income taxes paid (cash effect) (EUR) — -74.7M -72M -80M -120M -108M
Income detail
Total comprehensive income (EUR) — 224M 1.09B 772M 571M 949M
Comprehensive income to owners (EUR) — — 1.09B 771M 571M —
Reported Dec 8, 2022 Dec 8, 2022 Mar 10, 2023 Mar 15, 2024 Mar 15, 2024 Mar 19, 2025

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

26 October, 2026

  ![default](https://s7g10.scene7.com/is/image/kerry/leipzig_anniversary?ts=1792656886648&dpr=off&$IMAGE-Small$)

State-of-the-art facility supports innovation across food & beverage, biopharma and biotech applications

October 22, 2026 – Leipzig, Germany – Kerry , a global leader in taste and sustainable nutrition, is celebrating the one-year anniversary of operations at its Biotechnology Centre in Leipzig. This milestone underscores Kerry’s growing role as a key innovator in the global enzyme market, combining deep biotechnology capabilities with integrated application expertise to solve pressing customer challenges across the food and beverage, biopharma and biotech sectors.

The Kerry Biotechnology Centre in Leipzig, Germany plays a key role in further advancing Kerry’s biotechnology capabilities, giving our network of scientists access to state-of-the art bioinformatics, enzyme and strain engineering, machine learning and artificial intelligence (AI) modelling to enable the discovery of innovative biotechnology solutions, along with infrastructure to support fermentation and bioprocess development, scale-up, and production.

A Powerhouse for Enzyme Discovery and Scientific Innovation

The 10,000 m² Kerry Biotechnology Centre connects key technical teams under one roof, co-locating Enzyme Discovery and Enzyme Engineering in a shared laboratory environment to accelerate technical exchange and shorten development cycles. Over the past 12 months, Kerry’s Leipzig team achieved significant scientific and operational milestones, including:

  • Fungal Expression Breakthrough: Successfully producing enzymes in filamentous fungal cultures for the first time.
  • Proprietary ENESYZ Platform & Cloud Bioinformatics: Migrating KBC’s proprietary ENESYZ platform, supported by Next-Generation Sequencing (NGS), AI, and machine learning-assisted directed evolution, to a cloud-based architecture, democratizing advanced discovery tools across Kerry’s global sites.
  • Fast and efficient Enzyme discovery: Automated screening of 17,500 enzymes to successfully identify matching enzyme candidates
  • Commercialization of Next-Gen Biopharma Enzymes: Effectively launching CellTrypase , the first development launched directly from the new facility, and shipping Denarase® High Salt to 108 customer testing sites.
  • Regulatory & Sustainability Milestones for Coffee: Securing a positive European Food Safety Authority (EFSA) scientific safety opinion for Acrylerase®, a revolutionary new-to-world amidase enzyme providing a simple drop-in solution for acrylamide reduction in instant coffee and coffee substitutes without altering yield or taste.

“The perception of enzymes have evolved from simple processing aids into strategic innovation tools that allow food, beverage, and biopharma manufacturers to overcome complex market pressures without compromising on taste or quality,” said Ronan Moloney, Vice President, Enzymes at Kerry. “By bringing discovery, strain engineering, and pilot-scale production under one roof in Leipzig and pairing that with our proprietary ENESYZ bioinformatics platform, we are using machine learning to map enzyme sequences faster than ever. We’re incredibly proud of our integrated end-to-end model that enables us to turn complex biological science into scalable, commercially viable solutions that solve our customers’ toughest formulation and sustainability challenges.”

In its inaugural year, the Centre hosted more than 400 external guests across five major industry events, establishing the site as an essential hub for biotechnology innovation and cross-functional collaboration. As regulatory frameworks evolve and global demand for sustainable, resource-efficient solutions accelerates, Kerry will continue leveraging its biotechnology network to co-create high-impact solutions with customers worldwide.

About Kerry

Kerry is a global leader in taste and nutrition solutions. We innovate with our customers to create great-tasting products, with improved nutrition and functionality, while ensuring a better impact on the planet. Our leading consumer insights, global RD&A team of 1,300 scientists, and extensive global footprint enable us to solve our customers’ complex challenges with differentiated solutions. At Kerry, we are driven to be our customers’ most valued partner, creating a world of sustainable nutrition, and will reach over two billion consumers with sustainable nutrition solutions by 2030. For more information, visit www.kerry.com .   

FAQ

What is the Kerry Biotechnology Centre in Leipzig?

The Kerry Biotechnology Centre in Leipzig, Germany, brings together expertise in enzyme discovery, engineering, fermentation and bioprocess development. It supports biotechnology innovation across food, beverage and biopharma applications. 

How does Kerry develop enzyme solutions for food and beverage manufacturers?

Kerry combines enzyme discovery and engineering with application expertise, process development and manufacturing capabilities. This integrated approach helps translate scientific innovation into solutions for customers’ product and processing challenges. 

How are enzymes used in food and beverage production?

Enzymes can improve product quality and processing performance. Applications include improving dough performance and freshness in bakery products, supporting lactose-free and reduced-sugar dairy, and improving yield and throughput in beverage production.

How can enzymes support more sustainable food production?

Enzyme solutions can help manufacturers use raw materials more efficiently, extend product freshness and improve production processes. Kerry’s approach combines these opportunities with a focus on maintaining taste and product quality.

How does Kerry use AI in enzyme development?

Kerry uses bioinformatics, artificial intelligence and machine learning to support enzyme discovery and engineering. These tools complement scientific expertise, laboratory development and application testing to help identify and develop enzyme solutions. 

How does the Leipzig centre support customer innovation?

The centre brings scientific and technical teams together to support joint innovation with customers. Its capabilities span early-stage development, application trials, process scale-up and commercialisation support. 

What is Kerry’s Acrylerase® enzyme technology?

Acrylerase® is an enzyme solution developed to reduce acrylamide in instant coffee and coffee substitutes without altering yield or taste. It is one example of Kerry’s biotechnology expertise addressing specific food and beverage manufacturing challenges.

Related content:

  ![Taste Charts 2026](https://s7g10.scene7.com/is/image/kerry/Taste-Charts-2026-Hero_1920x1080?ts=1768314800099&dpr=off&$RELATED-Small$)

Food & Beverage Taste Charts 2026

Access insights

  ![2026 Supplements Taste Charts](https://s7g10.scene7.com/is/image/kerry/Supplements-Taste-Charts-2026-A-1203250_Digest_2832x1080px_F?ts=1768226054883&dpr=off&$RELATED-Small$)

Supplements Taste Charts 2026

Access insights

  ![Driving Flavour Innovation in 2026 with Taste Charts](https://s7g10.scene7.com/is/image/kerry/Taste-Charts-2026-1053374_Digest_2832x1080px_Hero_F?ts=1768226054867&dpr=off&$RELATED-Small$)

Driving Flavour Innovation in 2026 with Taste Charts

Read more

Kerry logo

Stay Connected

Contact Us

News & Media

Careers

Other Kerry Sites

Kerry Health & Nutrition Institute

Kerry.com

© Copyright 2026, Kerry Group plc. All rights Reserved

Company Information

Legal

Privacy

Cookie Policy

Speak Up

Modern Slavery Statements

Sitemap

Equal Pay Report Brazil

Transaction in Own Shares Bull 1 Bear 0 Routine

Released : 26/10/2026 07:00

RNS Number : 3054A

Kerry Group PLC

26 October 2026

26 October 2026

LEI: 635400TLVVBNXLFHWC59

KERRY GROUP PLC

Regulatory Announcement

TRANSACTION IN OWN SHARES

Kerry Group plc (“Kerry” or the “Company”) announces that from 19th October 2026 to 23rd October 2026 it purchased a total of 43,415 of its A ordinary shares of €0.125 each (the “Ordinary Shares”) on Euronext Dublin from J&E Davy. The Ordinary Shares purchased will be cancelled.

Date ofPurchase Number of shares purchased Trading Venue Lowest pricepaid Highest pricepaid
19/10/2026 3,511 Euronext Dublin €94.0000 €94.2000
20/10/2026 8,876 Euronext Dublin €94.1500 €94.5000
21/10/2026 10,255 Euronext Dublin €94.0000 €94.0000
22/10/2026 10,221 Euronext Dublin €96.5750 €96.7000
23/10/2026 10,552 Euronext Dublin €99.6000 €99.7500

The Ordinary Shares purchased form part of Kerry's intention to buyback Ordinary Shares of a total value of up to €300 million in the period up to 31 December 2026 at the latest (“Buyback Programme”). This Buyback Programme was announced on 17 February 2026 and formally commenced on 17 February 2026.

Following settlement of the above transactions and subsequent share cancellation Kerry will have,

157,581,736 Ordinary Shares in issue (excluding treasury shares).

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the “Market Abuse Regulation”) (including as it forms part of retained EU law in the United Kingdom ('UK') from time to time and, where relevant, pursuant to the UK's European Union (Withdrawal) Act 2018 and the UK's Market Abuse (Amendment) (EU Exit) Regulations 2019), a detailed breakdown of individual trades made by J&E Davy as riskless principal on behalf of Kerry on Euronext Dublin as part of the Buyback Programme for subsequent repurchase by the Company is scheduled to this announcement.

CONTACT INFORMATION
Group Secretary
Ronan Deasy
+353 66 7182000 | [email protected]
Website
www.kerry.com
Issuer name: Kerry Group plc
LEI 635400TLVVBNXLFHWC59
ISIN: IE0004906560
Intermediary name: J&E Davy
Intermediary code: DAVYIE21
Time zone: GMT
Currency: EUR
Euronext Dublin
Date of Purchase Number of Shares Price per Share (EUR) Trading Venue Trade Time MatchID
19/10/2026 2,500 94.2000 Euronext Dublin 15:01:56 00047245760TRLO1-1
19/10/2026 1,011 94.0000 Euronext Dublin 16:09:47 00047246570TRLO1-1
20/10/2026 6,211 94.1500 Euronext Dublin 08:23:53 00047247728TRLO1-1
20/10/2026 2,665 94.5000 Euronext Dublin 08:58:56 00047248263TRLO1-1
21/10/2026 10,255 94.0000 Euronext Dublin 15:16:06 00047265328TRLO1-1
22/10/2026 4,666 96.7000 Euronext Dublin 08:05:50 00047267847TRLO1-1
22/10/2026 5,555 96.5750 Euronext Dublin 08:42:01 00047268276TRLO1-1
23/10/2026 4,652 99.7500 Euronext Dublin 13:30:25 00047278808TRLO1
23/10/2026 2,800 99.6000 Euronext Dublin 09:26:49 00047276815TRLO1
23/10/2026 3,100 99.6000 Euronext Dublin 09:49:32 00047276954TRLO1

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com .

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy .

END

POSMJBITMTATBJF

Presentation Bull 3 Bear 0 Results

Q3 2026 Results 22 October 2026

Disclaimer: Forward Looking Statements This presentation/announcement may contain forward looking statements with projections regarding, among other things, Kerry’s strategy, revenues, earnings, EBITDA, EBITDA margin, finance costs, tax rate, capital expenditure, dividends, share buybacks, cash flow, net debt or other financial measures, the impact of foreign exchange fluctuations, the impact of input cost fluctuations and other competitive pressures. These and other forward looking statements reflect management expectations based on currently available data. However, actual results will be influenced by, among other things, macro-economic conditions, food industry supply and demand issues, foreign exchange fluctuations, raw material and commodity fluctuations, the successful acquisition and integration of new businesses, the successful execution of business transformation programmes and other, as of today, unknown factors. Therefore actual results may differ materially from these projections. These forward looking statements speak only as of the date they were made and Kerry undertakes no obligation to publicly update any forward looking statement, whether as a result of new information, future events or otherwise.

© Kerry 2026 | 2

Q3 Results 2026

Edmond Scanlon Chief Executive Officer

Marguerite Larkin Chief Financial Officer

© Kerry 2026 | 3

Strong Q3 Volume Growth and Continued Margin Expansion

Volume Growth

EBITDA Margin Expansion

2026 YTD

2024 – 2026YTD

4.1%

+50bps +80bps

3.5% 3.1% +120bps

Q1

Q2

Q3

2024

2025

2026 YTD

© Kerry 2026 | 4

Investor Day 2026 – Key Messages

  1. A Highly Dynamic Market – Particularly Attractive for Kerry
  2. Industry’s Most Relevant Technology Portfolio & Business Model
  3. In Execution mode both Strategy & Financial Performance Accelerating Innovation Through Biotechnology

Renovation for Dynamic Market Needs

Pioneering Next Generation Taste

Foodservice A Structural Tailwind

Digital Transformation Enabling Business Strategy and Financial Delivery

© Kerry 2026 | 5

Summary Q3 YTD Financial Overview

Volume Growth

+3.6% (Q3: +4.1%)

EBITDA Margin Expansion

+50bps

© Kerry 2026 | 6

Q3 YTD 2026 Business Performance Review

A Further Step-Up in Volume Growth •

Volume growth of 3.6% (Q3: +4.1%) well ahead of end market growth

•

Pricing of -0.6% (Q3: +0.2%) with deflation in H1 turning to inflation in Q3

•

EBITDA margin expansion of 50bps primarily driven by Accelerate 2.0

•

EUMs: Led by Snacks, Meat, Dairy and Beverage

•

Channel: Foodservice volume growth of 5.0% with retail performing well

•

Emerging markets volume growth of 4.9% led by a strong performance in the Middle East and Africa © Kerry 2026 | 7

Regional Review AMERICAS

+4.0% (Q3: +4.6%)

EUROPE

+0.7% (Q3: +1.3%)

• North America growth led by

• Volume progression

• Strong growth in foodservice

• Growth led by Beverage,

• LATAM growth led by Mexico

• Retail and foodservice

Snacks, Beverage & Meat

with retail performing well

Note: Volume growth shown above

through the year Snacks & Dairy

growth similar to overall region

APMEA

+5.2% (Q3: +5.7%)

• Strong growth in Middle

East & Africa, a good performance in South Asia Pacific, with growth in China

• Growth led by Dairy, Meat,

Snacks & Bakery

• Growth led by retail, with

foodservice performing well © Kerry 2026 | 8

Revenue Analysis Q3 YTD 2025

Q3 YTD 2026 -0.6%

Transaction FX Translation FX

-2.5%

-0.2%

Volume

+3.6%

Price

-0.6%

Acquisitions / Disposals

-0.9%

© Kerry 2026 | 9

Other Financial Matters

Net Debt

€2.4bn at period end, reflecting cash generation, the share buyback programme and timing of capital investments

Share Buybacks

Intention to initiate new programme post completion of existing programme

Accelerate 2.0

Progressing as planned with footprint optimisation & digital initiatives

Input costs

H1 deflation turned to inflation in H2

Currency

FY 2026 EPS translation outlook of ~1% headwind

© Kerry 2026 | 10

FY 2026 Outlook →

Kerry’s continued strong end market outperformance highlights the strength and relevance of its strategic positioning across its markets, channels and customer base.

→

The Group will continue to further advance its strategic business development, while supporting its customers as their key innovation and renovation partner.

→

While recognising macro and geopolitical uncertainty, Kerry remains strongly positioned for volume growth and margin expansion, underpinned by a good innovation and renovation pipeline.

→

Kerry maintains its constant currency adjusted earnings per share guidance of 6% to 10% growth in 2026.

Note: Foreign currency translation expected to be a headwind of ~1% on adjusted earnings per share in 2026 | Guidance based on average number of shares in issue of ~160m.

© Kerry 2026 | 11

Appendix

Financial Metric Definitions Volume Growth This represents the sales performance period-on-period, excluding pass-through pricing on input costs, currency impacts, acquisitions, disposals and rationalisation volumes. Organic Growth This represents the performance period-on-period, excluding translation currency impacts, acquisitions, disposals and rationalisation volumes. EBITDA EBITDA represents profit before taxation and before finance income and costs, other income, depreciation (net of capital grant amortisation), intangible asset amortisation, non-trading items and share of joint ventures’ results after taxation. Net Debt Net debt comprises borrowings and overdrafts, interest rate derivative financial instruments, lease liabilities and cash at bank and in hand. Cash Conversion Cash conversion is defined as free cash flow, expressed as a percentage of adjusted earnings after taxation.

Free Cash Flow Free cash flow is EBITDA plus movement in average working capital, capital expenditure net (purchase of assets, payment of lease liabilities, inflow from the sale of assets (net of disposal expenses) and capital grants received), pension contributions paid less pension expense, finance costs paid (net), other income and income taxes paid. Average working capital is the sum of each month’s working capital over 12 months adjusted for the impact of acquisitions and disposals. Return on Average Capital Employed (ROACE) ROACE is defined as profit after taxation attributable to equity holders of the parent before non-trading items (net of related tax), brand related intangible asset amortisation and finance income, costs and other income expressed as a percentage of average capital employed. Average Capital Employed Average capital employed is the average of total capital employed over the last three reported balance sheets. Total capital employed is calculated as shareholders’ equity, less the vendor loan note relating to the Sweet Ingredients Portfolio, less the Retained Investment in Kinisla Group Limited, plus net debt.

© Kerry 2026 | 13

Q3 2026 Results 22 October 2026

Prompts

Kerry Group plc (ticker KYGA), listed in United Kingdom.

ETFs Holding Kerry Group plc

ETF Weight in ETF Shares Market value As of
QLTI 3.83% 116,550 $ 11.372M Aug 31, 2026
TMFG 1.79% 65,021 $ 6.344M Aug 31, 2026
FPAG 1.78% 104,505 $ 9.594M Jun 30, 2026
DSTX 1.03% 5,297 $ 486.605K Jun 30, 2026
ILOW 0.74% 142,185 $ 13.874M Aug 31, 2026
SROI 0.71% 1,393 $ 133.005K Jul 31, 2026
DFIS 0.15% 76,927 $ 8.573M Nov 12, 2026
DFIC 0.08% 109,858 $ 12.243M Nov 12, 2026
DFAI 0.07% 108,083 $ 12.045M Nov 12, 2026
DFAX 0.06% 69,485 $ 7.743M Nov 12, 2026
NTSI 0.06% 3,090 $ 283.86K Jun 30, 2026
DXIV 0.06% 1,230 $ 137.07K Nov 12, 2026
DFSI 0.05% 5,665 $ 631.304K Nov 12, 2026
AVDE 0.02% 32,288 $ 3.602M Nov 16, 2026
AVSD 0.02% 771 $ 86.011K Nov 16, 2026
DIHP 0.02% 9,837 $ 1.096M Nov 12, 2026
DISV 0.01% 6,005 $ 669.194K Nov 12, 2026

Securities

Ticker Type Class Market Exchange Last price Price date
KYGA canonical Common share — GB lse 75.47 EUR 2026-06-12
KRZ Common share — IE euronext — —